AU · rank #14 · 2026-10-23
IOVA
NASDAQ · $6.73B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.091 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.207 |
| Analyst upside Consensus target $14.40 | +1.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +137.53% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.40 |
| Gross margin TTM | +48.4% |
| 52w high | $15.30 |
| Market cap (USD) | $6.73B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Iovance Biotherapeutics is the only company with an FDA-approved commercial TIL therapy (Amtagvi) for advanced melanoma, generating ~$400M annualized revenue with a 100-center authorized treatment network and a pipeline extending into sarcoma and NSCLC.
Rationale
The analyst_upside signal is reinforced by 100% revision agreement across 8 analysts, four target raises in 30 days, a strong 18.4% earnings surprise, and 66% YoY revenue growth with raised guidance — all pointing to a consensus view that estimates are still catching up to commercial execution.
Material risks
- 1Revenue concentration in a single approved indication (previously treated advanced melanoma) means any slowdown in treatment-center activation, reimbursement friction, or patient referral bottlenecks directly collapses the growth narrative underpinning the target raises.
- 2Obsidian's OBX-115 and other outpatient-biopsy TIL approaches could erode Iovance's manufacturing-complexity moat before pipeline diversification (NSCLC, sarcoma) is clinically validated, compressing the window in which current analyst targets are achievable.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.